This is an amazing honour that has only happened with the help of many patients, collaborators, colleagues and students with whom I have worked. I am deeply grateful to everyone, and so pleased to be part of headache science coming of age and improving patients' lives.Professor Peter Goadsby, Director of NIHR/Wellcome King’s Clinical Research Facility and Professor of Neurology
10 May 2022
Professor Peter Goadsby elected to the Fellowship of the Royal Society
Professor Peter Goadsby from the Institute of Psychiatry, Psychology & Neuroscience (IoPPN) has been elected to the Fellowship of the Royal Society, a Fellowship of many of the world’s most eminent scientists and the oldest academy in continuous existence.
Each year up to 52 Fellows and up to 10 Foreign Members are elected from a group of around 800 candidates who are proposed by the existing Fellowship, in recognition of their exceptional contributions to science, engineering and medicine.
Professor Goadsby is the Director of the Director of the National Institute for Health and Care Research (NIHR)-Wellcome King’s Clinical Research Facility, as well as a Professor of Neurology in the School of Neuroscience. In a career that has spanned four decades, he is one of the leading researchers exploring the science behind migraine and cluster headache. He has continually sought to understand the mechanisms behind migraine, often challenging accepted opinion in an effort expand our understanding of an illness which affects about 1 in 6 people.
In 2021, Professor Goadsby was one of a group of four scientists awarded the Brain Prize - one of the world’s most prestigious awards in neuroscience – in recognition of his pioneering research that led to the development of entirely new and effective classes of migraine treatments.
Professor Mark Richardson, Head of School of Neuroscience, added "Fellowship of the Royal Society is yet another important accolade, recognising Peter’s work in fundamental and translational neuroscience. His work on migraine and headache disorders has greatly improved our understanding of these conditions and led to novel therapies, with important benefits for patients suffering from these common problems. We are extremely fortunate to have such a world-class talent in our school."
For further information, please contact Patrick O’Brien (Senior Media Officer)